Envisia Therapeutics To Present At AAO 2016 Annual Meeting

RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2016 /PRNewswire/ -- Envisia Therapeutics today announced that Dr. Thomas R. Walters, MD will present breakthrough clinical data for Envisia's ENV515 (travoprost XR) glaucoma program at the American Academy of Ophthalmology (AAO) Annual Meeting being held October 15 – 18, 2016 in Chicago, IL. AAO annual meeting is the largest gathering of US-based ophthalmologists.

"AAO meeting continues to be the preeminent venue for clinical research in ophthalmology and we are very pleased to have the opportunity to present breakthrough data for our glaucoma program," said Benjamin Yerxa, PhD, President of Envisia Therapeutics. "We are incredibly proud of the progress we have made and welcome the opportunity to showcase that progress at this world-renowned meeting."

Details related to the Envisia presentation are as follows:

Monday, October 17, 2016

Poster #PO410: Interim 3-Month Safety and Efficacy Evaluation of Low-Dose Intracameral ENV515 Travoprost XR in 12-Month Study in Glaucoma Patients

• McCormick Place, South Hall A, 12:30pm – 2:00 pm, Monday, October 17, 2016
• Presented by Dr. Thomas R. Walters, MD, Austin, TX

ENV515 is a fully biodegradable PRINT-particle formulation of a marketed prostaglandin analog that has the potential to lower intraocular pressure (IOP) for more than 6 months from a single dose. ENV515 was designed to address the issue of poor patient compliance that exists today with daily eye drops and limit the progression of glaucoma that sometimes leads to vision loss. Envisia is also leveraging the Company's unique platform technology to develop products for other leading ocular diseases, including age-related macular degeneration (AMD) and diabetic macular edema (DME).

ABOUT ENVISIA THERAPEUTICS™
Envisia Therapeutics is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® technology platform to develop therapies for a variety of ocular conditions, beginning with ENV515 for glaucoma. ENV515 is a novel, extended-release formulation of a marketed prostaglandin analogue with the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is actively exploring the use of the company's unique technology to develop products for other important ocular diseases including age-related macular degeneration (AMD) and diabetic macular edema (DME). Envisia is located in Research Triangle Park, North Carolina. For more information, please go to www.envisiatherapeutics.com.

SOURCE Envisia Therapeutics

Related Links

http://www.envisiatherapeutics.com